Nobilis IB 4-91

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

živi atenuirani varijantu soja 4-91 virusnih infektivnih bronhitisa

Available from:

Intervet International BV

ATC code:

QI01AD07

INN (International Name):

live attenuated vaccine against avian infectious bronchitis

Therapeutic group:

Piletina

Therapeutic area:

Imunološki za aves

Therapeutic indications:

Aktivna imunizacija pilića radi smanjenja respiratornih znakova infektivnog bronhitisa uzrokovanog varijantom soja IB 4-91.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

1998-06-09

Patient Information leaflet

                                17
B. UPUTA O VMP
18
UPUTA O VMP
NOBILIS IB 4-91, LIOFILIZAT ZA OKULONAZALNU SUSPENZIJU / PRIMJENU U
VODI ZA PIĆE ZA PILIĆE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobilis IB 4-91, liofilizat za okulonazalnu suspenziju / primjenu u
vodi za piće za piliće
3.
NAVOĐENJE DJELATNE TVARI I DRUGIH SASTOJAKA
Živi, atenuirani virus zaraznog bronhitisa kokoši (ZBK), varijantni
soj 4-91: ≥ 3,6 log10 EID
50
* po
dozi
* EID
50
: 50% embrio infektivna doza: titar virusa koji uzrokuje infekciju u
50% virusom inokuliranih
embrija.
Liofilizat za
OKULONAZALNU SUSPENZIJU / PRIMJENU U VODI ZA PIĆE
Bočice: krem bijela obojana peleta.
Čašice: krem bijeli, pretežito okrugli oblici.
4.
INDIKACIJE
Aktivna imunizacija pilića za smanjenje respiratornih znakova
zaraznog bronhitisa, uzrokovanih
varijantnim sojem ZB 4-91.
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
U laboratorijskim i terenskim istraživanjima:
Cjepljenje sa Nobilis IB 4-91 često može uzrokovati blage
respiratorne simptome bolesti koje mogu
trajati nekoliko dana ovisno o zdravlju i kondiciji pilića.
U iskustvima nakon stavljanja na tržište:
U vrlo rijetkim slučajevima prijavljeni su blagi respiratorni
simptomi bolesti.
Učestalost nuspojava je određena prema slijedećim pravilima:
-
vrlo česte (više od 1 u 10 životinja pokazuju nuspojave za vrijeme
trajanja jednog tretmana)
-
česte (više od jedne ali manje od 10 životinja od 100 životinja)
-
manje česte (više od 1 ali manje od 10 životinja na 1000
životinja)
19
-
rijetke (više od 1 ali manje od 10 životinja na 10,000 životinja)
-
vrlo rijetke (manje od 1 životinje na 10,000 životinja,
uključujući izolirane slučajeve).
Ako zamijetite bilo koju nuspojavu, čak
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobilis IB 4-91, liofilizat za okulonazalnu suspenziju / primjenuu
vodi za piće, za piliće
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza rekonstituirane vakcine sadrži:
DJELATNA TVAR:
Živi, atenuirani virus zaraznog bronhitisa kokoši (ZBK), varijantni
soj 4-91: ≥ 3,6 log 10 EID
50
*
*
EID
50
: 50% embrio infektivna doza: titar virusa koji uzrokuje infekciju u
50% virusom inokuliranih
embrija.
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Liofilizat za okulonazalnu suspenziju / primjenu u vodi za piće,
Bočice: krem bijela obojana peleta
Čašice: krem bijeli, pretežito okrugli oblici
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Pilići.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Aktivna imunizacija pilića za smanjenje respiratornih znakova
zaraznog bronhitisa uzrokovanih
varijantnim sojem IB 4-91.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Cijepiti samo zdrave životinje.
Cjepni virus može se širiti s cijepljenih pilića na necijepljene,
pa treba poduzeti odgovarajuće mjere da
cijepljeni pilići budu odvojeni od necijepljenih.
Nakon cijepljenja oprati i dezinficirati ruke i opremu, kako bi se
izbjeglo širenje virusa.
4.5
POSEBNE MJERE OPREZA ZA PRIMJENU
Posebne mjere opreza za primjenu na životinjama
Vakcina Nobilis IB 4-91 je namijenjena za zaštitu pilića protiv
respiratornih znakova bolesti
uzrokovanih varijantnim sojem virusa zaraznog bronhitisa kokoši 4-91
i ne smije se koristiti kao
zamjena za druga cjepiva, za virus ZB. Proizvod treba primijeniti
samo, nakon što je utvrđeno da je
3
virus ZB, varijantni soj 4-91, epidemiološki relevantan u tom
području. Treba paziti da se varijantni
soj ne prenese u područje gdje nije prisutan.
Posebne mjere opreza valja primijeniti da se cjepni virus ne proširi
s cijepljenih pilića na fazane.
Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje
veterinarsko-me
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-04-2021
Public Assessment Report Public Assessment Report Bulgarian 08-07-2015
Patient Information leaflet Patient Information leaflet Spanish 26-04-2021
Public Assessment Report Public Assessment Report Spanish 08-07-2015
Patient Information leaflet Patient Information leaflet Czech 26-04-2021
Public Assessment Report Public Assessment Report Czech 08-07-2015
Patient Information leaflet Patient Information leaflet Danish 26-04-2021
Public Assessment Report Public Assessment Report Danish 08-07-2015
Patient Information leaflet Patient Information leaflet German 26-04-2021
Public Assessment Report Public Assessment Report German 08-07-2015
Patient Information leaflet Patient Information leaflet Estonian 26-04-2021
Public Assessment Report Public Assessment Report Estonian 08-07-2015
Patient Information leaflet Patient Information leaflet Greek 26-04-2021
Public Assessment Report Public Assessment Report Greek 08-07-2015
Patient Information leaflet Patient Information leaflet English 11-02-2019
Public Assessment Report Public Assessment Report English 08-07-2015
Patient Information leaflet Patient Information leaflet French 26-04-2021
Public Assessment Report Public Assessment Report French 08-07-2015
Patient Information leaflet Patient Information leaflet Italian 26-04-2021
Public Assessment Report Public Assessment Report Italian 08-07-2015
Patient Information leaflet Patient Information leaflet Latvian 26-04-2021
Public Assessment Report Public Assessment Report Latvian 08-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-04-2021
Public Assessment Report Public Assessment Report Lithuanian 08-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-04-2021
Public Assessment Report Public Assessment Report Hungarian 08-07-2015
Patient Information leaflet Patient Information leaflet Maltese 26-04-2021
Public Assessment Report Public Assessment Report Maltese 08-07-2015
Patient Information leaflet Patient Information leaflet Dutch 26-04-2021
Public Assessment Report Public Assessment Report Dutch 08-07-2015
Patient Information leaflet Patient Information leaflet Polish 26-04-2021
Public Assessment Report Public Assessment Report Polish 08-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 26-04-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-04-2021
Public Assessment Report Public Assessment Report Portuguese 08-07-2015
Patient Information leaflet Patient Information leaflet Romanian 26-04-2021
Public Assessment Report Public Assessment Report Romanian 08-07-2015
Patient Information leaflet Patient Information leaflet Slovak 26-04-2021
Public Assessment Report Public Assessment Report Slovak 08-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-04-2021
Public Assessment Report Public Assessment Report Slovenian 08-07-2015
Patient Information leaflet Patient Information leaflet Finnish 26-04-2021
Public Assessment Report Public Assessment Report Finnish 08-07-2015
Patient Information leaflet Patient Information leaflet Swedish 26-04-2021
Public Assessment Report Public Assessment Report Swedish 08-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 26-04-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-04-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-04-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-04-2021